Biocon Pharma gets tentative US FDA approval for Parkinson's treatment

• Biocon Pharma Ltd received tentative FDA approval for carbidopa and levodopa extended-release capsules.
• The approved capsules treat Parkinson's disease, post-encephalitic Parkinsonism, and Parkinsonism from carbon monoxide or manganese intoxication.
• The FDA approval covers all four submitted strengths of the carbidopa and levodopa capsules.
• Biocon's board will meet to review proposals for investment in its subsidiary, Biocon Biologics Ltd, and a broader capital-raising plan.

Why It Matters: Biocon's FDA approval for Parkinson's drug offers new treatment options.